Skip to main content
Pharmicell Co.,Ltd. logo

Pharmicell Co.,Ltd. — Investor Relations & Filings

Ticker · 005690 ISIN · KR7005690003 KO Manufacturing
Open in API
Filings indexed 275 across all filing types
Latest filing 2026-05-12 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 005690

About Pharmicell Co.,Ltd.

https://www.pharmicell.com/eng/

Pharmicell Co., Ltd. is a biopharmaceutical company specializing in stem cell technology and advanced bio-based materials. The company is a pioneer in regenerative medicine, having developed Hearticellgram-AMI, the world's first approved stem cell therapy for acute myocardial infarction. Its core business includes the development of stem cell therapeutics, a stem cell banking service for adult and cord blood cells, and a line of cosmetics based on stem cell culture media. A significant division focuses on fine chemicals, manufacturing and supplying critical raw materials for the pharmaceutical industry, such as nucleosides, mPEGs, and oligonucleotides for gene therapies. The company also produces eco-friendly flame retardants for industrial use.

Recent filings

Filing Released Lang Actions
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 95% confidence The document is a Korean 분기보고서 (59th quarterly report) covering the period 2026-01-01 to 2026-03-31, containing detailed financial statements, notes, and management discussion. This is a comprehensive interim/quarterly report, matching the definition of an Interim / Quarterly Report (IR). Q1 2026
2026-05-12 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 85% confidence The document is a regulatory filing disclosing the grant (and subsequent correction) of stock options (“주식매수선택권 부여”) by the company to its directors and employees. This constitutes an issuance of new share-based instruments and a change in capital structure rather than a pure financial report or management presentation. Under the classification scheme, announcements of new share issues or capital changes, including option grants, fall under Share Issue/Capital Change (SHA).
2026-05-12 Korean
단일판매ㆍ공급계약체결
Regulatory Filings
2026-05-08 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 90% confidence The document is a regulatory ‘주식등의 대량보유상황보고서’ (Report on Large Shareholdings) filed under Korea’s Capital Market Act, detailing significant share ownership changes by a major shareholder and related parties. This corresponds to a Major Shareholding Notification (crossing ownership thresholds).
2026-04-15 Korean
기업설명회(IR)개최(안내공시)
Investor Presentation Classification · 82% confidence The document is a notice (안내공시) announcing the date, time, venue, participants, and format of an upcoming corporate investor presentation (기업설명회/IR). Although it is not the presentation slide deck itself, it clearly relates to investors and outlines an IR event, matching the Investor Presentation category.
2026-04-01 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 93% confidence The document is titled “정기주주총회 결과” (Results of the regular shareholders’ meeting), dated 2026-03-26, and lists each agenda item resolution, voting percentages, approval status (e.g., approval of financial statements, dividend resolution, director appointments, amendments to the articles of incorporation). It is clearly reporting the voting results of an Annual General Meeting rather than proposing or soliciting votes. This matches the definition of “Declaration of Voting Results & Voting Rights Announcements” (DVA).
2026-03-26 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.